{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T13:35:31Z","timestamp":1654263331213},"reference-count":86,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2005,7,1]],"date-time":"2005-07-01T00:00:00Z","timestamp":1120176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Nephrology"],"published-print":{"date-parts":[[2005,7]]},"DOI":"10.1016\/j.semnephrol.2005.02.004","type":"journal-article","created":{"date-parts":[[2008,9,21]],"date-time":"2008-09-21T09:22:07Z","timestamp":1221988927000},"page":"198-209","source":"Crossref","is-referenced-by-count":6,"title":["Hypertension Treatment Guidelines: Practical Implications"],"prefix":"10.1016","volume":"25","author":[{"given":"Kenneth L.","family":"Choi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George L.","family":"Bakris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.semnephrol.2005.02.004_bib1","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1161\/01.HYP.0000107251.49515.c2","article-title":"Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure","volume":"42","author":"Chobanian","year":"2003","journal-title":"Hypertension"},{"key":"10.1016\/j.semnephrol.2005.02.004_bib2","first-page":"S1","article-title":"Summary of Revisions for the 2004 Clinical Practice Recommendations","volume":"27","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.semnephrol.2005.02.004_bib3","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1097\/00004872-200306000-00001","article-title":"2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension","volume":"21","year":"2003","journal-title":"J Hypertens"},{"key":"10.1016\/j.semnephrol.2005.02.004_bib4","first-page":"1","article-title":"K\/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease","volume":"43","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2005.02.004_bib5","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(02)11911-8","article-title":"Age-specific relevance of usual blood pressure to vascular mortality","volume":"360","author":"Lewington","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.semnephrol.2005.02.004_bib6","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1136\/bmj.317.7160.703","article-title":"Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes","volume":"317","year":"1998","journal-title":"BMJ"},{"key":"10.1016\/j.semnephrol.2005.02.004_bib7","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/S0140-6736(98)04311-6","article-title":"Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension","volume":"351","author":"Hansson","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.semnephrol.2005.02.004_bib8","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1053\/ajkd.2000.16225","article-title":"Preserving renal function in adults with hypertension and diabetes","volume":"36","author":"Bakris","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2005.02.004_bib9","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1001\/archinte.160.9.1277","article-title":"Cost-effectiveness of the lower treatment goal (of JNC VI) for diabetic hypertensive patients","volume":"160","author":"Elliott","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.semnephrol.2005.02.004_bib10","doi-asserted-by":"crossref","first-page":"244","DOI":"10.7326\/0003-4819-139-4-200308190-00006","article-title":"Progression of chronic kidney disease: The role of blood pressure, proteinuria, and angiotensin-converting enzyme inhibition. A patient-level meta-analysis","volume":"39","author":"Jafar","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semnephrol.2005.02.004_bib11","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1046\/j.1523-1755.2002.00213.x","article-title":"Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes","volume":"61","author":"Schrier","year":"2002","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2005.02.004_bib12","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1001\/jama.288.19.2421","article-title":"Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease","volume":"288","author":"Wright","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.semnephrol.2005.02.004_bib13","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1001\/jama.265.24.3255","article-title":"Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP)","volume":"265","year":"1991","journal-title":"JAMA"},{"key":"10.1016\/j.semnephrol.2005.02.004_bib14","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1001\/jama.284.4.465","article-title":"Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke","volume":"284","author":"Perry","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.semnephrol.2005.02.004_bib15","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1161\/01.HYP.35.2.544","article-title":"Long-term effects of weight loss and dietary sodium reduction on incidence of hypertension","volume":"35","author":"He","year":"2000","journal-title":"Hypertension"},{"key":"10.1016\/j.semnephrol.2005.02.004_bib16","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1001\/jama.279.11.839","article-title":"Sodium reduction and weight loss in the treatment of hypertension in older persons","volume":"279","author":"Whelton","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.semnephrol.2005.02.004_bib17","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1001\/jama.289.16.2083","article-title":"Effects of comprehensive lifestyle modification on blood pressure control","volume":"289","author":"Appel","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.semnephrol.2005.02.004_bib18","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1001\/archinte.157.6.657","article-title":"Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure. The Trials of Hypertension Prevention, phase II","volume":"157","year":"1997","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.semnephrol.2005.02.004_bib19","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1081\/CEH-100108713","article-title":"Effects of alcohol consumption and restriction on home blood pressure in hypertensive patients","volume":"24","author":"Kawano","year":"2002","journal-title":"Clin Exp Hypertens"},{"key":"10.1016\/j.semnephrol.2005.02.004_bib20","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1097\/00004872-200306000-00009","article-title":"Do the ethanol metabolizing enzymes modify the relationship between alcohol consumption and blood pressure?","volume":"21","author":"Saito","year":"2003","journal-title":"J Hypertens"},{"key":"10.1016\/j.semnephrol.2005.02.004_bib21","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJM199704173361601","article-title":"A clinical trial of the effects of dietary patterns on blood pressure","volume":"336","author":"Appel","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2005.02.004_bib22","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1056\/NEJM200101043440101","article-title":"Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet","volume":"344","author":"Sacks","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2005.02.004_bib23","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1161\/01.HYP.33.1.586","article-title":"Effects of smoking cessation on blood pressure and heart rate variability in habitual smokers","volume":"33","author":"Minami","year":"1999","journal-title":"Hypertension"},{"key":"10.1016\/j.semnephrol.2005.02.004_bib24","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/S0895-7061(98)00137-X","article-title":"Ambulatory 24-h blood pressure monitoring in healthy, middle-aged smokeless tobacco users, smokers, and nontobacco users","volume":"11","author":"Bolinder","year":"1998","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.semnephrol.2005.02.004_bib25","doi-asserted-by":"crossref","first-page":"493","DOI":"10.7326\/0003-4819-136-7-200204020-00006","article-title":"Effect of aerobic exercise on blood pressure","volume":"136","author":"Whelton","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semnephrol.2005.02.004_bib26","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","article-title":"Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic","volume":"288","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.semnephrol.2005.02.004_bib27","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1001\/jama.283.15.1967","article-title":"Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone","volume":"283","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.semnephrol.2005.02.004_bib28","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/S0140-6736(03)14739-3","article-title":"Effects of different blood-pressure-lowering regimens on major cardiovascular events","volume":"362","author":"Turnbull","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.semnephrol.2005.02.004_bib29","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1001\/archinte.150.8.1707","article-title":"A comparison of the efficacy and safety of a beta-blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks","volume":"150","author":"Saunders","year":"1990","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.semnephrol.2005.02.004_bib30","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1056\/NEJM200105033441802","article-title":"Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction","volume":"344","author":"Exner","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2005.02.004_bib31","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1097\/00004872-200305000-00011","article-title":"The Study on Cognition and Prognosis in the Elderly (SCOPE)","volume":"21","author":"Lithell","year":"2003","journal-title":"J Hypertens"},{"key":"10.1016\/j.semnephrol.2005.02.004_bib32","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0140-6736(99)12323-7","article-title":"Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus","volume":"355","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.semnephrol.2005.02.004_bib33","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S0895-7061(04)00840-4","article-title":"Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial","volume":"17","author":"Jamerson","year":"2004","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.semnephrol.2005.02.004_bib34","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1161\/01.CIR.0000129307.26791.8E","article-title":"Impaired endothelium-dependent flow-mediated vasodilation in hypertensive subjects with hyperaldosteronism","volume":"109","author":"Nishizaka","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.semnephrol.2005.02.004_bib35","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1378\/chest.125.1.112","article-title":"Aldosterone excretion among subjects with resistant hypertension and symptoms of sleep apnea","volume":"125","author":"Calhoun","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.semnephrol.2005.02.004_bib36","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1161\/01.HYP.0000025146.19104.FE","article-title":"Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients","volume":"40","author":"Krum","year":"2002","journal-title":"Hypertension"},{"key":"10.1016\/j.semnephrol.2005.02.004_bib37","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0002-9149(03)00461-2","article-title":"Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension","volume":"92","author":"White","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.semnephrol.2005.02.004_bib38","doi-asserted-by":"crossref","first-page":"901","DOI":"10.7326\/0003-4819-139-11-200312020-00008","article-title":"Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy","volume":"139","author":"Wachtell","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semnephrol.2005.02.004_bib39","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1161\/01.CIR.0000139860.33974.28","article-title":"Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy","volume":"110","author":"De Zeeuw","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.semnephrol.2005.02.004_bib40","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1161\/01.CIR.0000031732.78052.81","article-title":"Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population","volume":"106","author":"Hillege","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.semnephrol.2005.02.004_bib41","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/j.1524-6175.2002.01641.x","article-title":"ACE inhibitors and protection against kidney disease progression in patients with type 2 diabetes","volume":"4","author":"Bakris","year":"2002","journal-title":"J Clin Hypertens"},{"key":"10.1016\/j.semnephrol.2005.02.004_bib42","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1046\/j.1523-1755.1998.00083.x","article-title":"Effects of an ACE inhibitor\/calcium antagonist combination on proteinuria in diabetic nephropathy","volume":"54","author":"Bakris","year":"1998","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2005.02.004_bib43","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0272-6386(03)00410-4","article-title":"The verapamil versus amlodipine in nondiabetic nephropathies treated with trandolapril (VVANNTT) study","volume":"42","author":"Boero","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2005.02.004_bib44","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(03)12229-5","article-title":"Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE)","volume":"361","author":"Nakao","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.semnephrol.2005.02.004_bib45","doi-asserted-by":"crossref","first-page":"200S","DOI":"10.1016\/S0895-7061(96)00392-5","article-title":"Salt intake and reductions in arterial pressure and proteinuria","volume":"9","author":"Bakris","year":"1996","journal-title":"Is there a direct link? Am J Hypertens"},{"key":"10.1016\/j.semnephrol.2005.02.004_bib46","doi-asserted-by":"crossref","first-page":"754","DOI":"10.7326\/0003-4819-123-10-199511150-00003","article-title":"Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study","volume":"123","author":"Peterson","year":"1995","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semnephrol.2005.02.004_bib47","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1001\/archinte.163.13.1555","article-title":"Effects of blood pressure level on progression of diabetic nephropathy","volume":"163","author":"Bakris","year":"2003","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.semnephrol.2005.02.004_bib48","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1001\/archinte.160.5.685","article-title":"Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine","volume":"160","author":"Bakris","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.semnephrol.2005.02.004_bib49","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S0895-7061(03)00913-0","article-title":"Aldosterone breakthrough during angiotensin-converting enzyme inhibitor therapy","volume":"16","author":"Sato","year":"2003","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.semnephrol.2005.02.004_bib50","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1177\/147323000102900103","article-title":"Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy","volume":"29","author":"Sato","year":"2001","journal-title":"J Int Med Res"},{"key":"10.1016\/j.semnephrol.2005.02.004_bib51","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/ki.1982.14","article-title":"Plasma aldosterone concentrations in chronic renal disease","volume":"21","author":"Hene","year":"1982","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2005.02.004_bib52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1523-1755.2004.00701.x","article-title":"Aldosterone in the development and progression of renal injury","volume":"66","author":"Hollenberg","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2005.02.004_bib53","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1097\/01.ASN.0000086472.65806.73","article-title":"Aldosterone in chronic kidney and cardiac disease","volume":"14","author":"Hostetter","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2005.02.004_bib54","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1161\/01.HYP.0000044937.95080.E9","article-title":"Effectiveness of aldosterone blockade in patients with diabetic nephropathy","volume":"41","author":"Sato","year":"2003","journal-title":"Hypertension"},{"key":"10.1016\/j.semnephrol.2005.02.004_bib55","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1056\/NEJM200109203451215","article-title":"Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease","volume":"345","author":"Chrysostomou","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2005.02.004_bib56","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJM200003303421301","article-title":"Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study","volume":"342","author":"Gress","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2005.02.004_bib57","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1056\/NEJM200003303421310","article-title":"Antihypertensive therapy and the risk of type 2 diabetes mellitus","volume":"342","author":"Sowers","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2005.02.004_bib58","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/sj.jhh.1000834","article-title":"Effectiveness and metabolic effects of perindopril and diuretics combination in primary hypertension","volume":"13","author":"Elisaf","year":"1999","journal-title":"J Hum Hypertens"},{"key":"10.1016\/j.semnephrol.2005.02.004_bib59","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1001\/jama.275.20.1549","article-title":"Long-term effects on plasma lipids of diet and drugs to treat hypertension","volume":"275","author":"Grimm","year":"1996","journal-title":"JAMA"},{"key":"10.1016\/j.semnephrol.2005.02.004_bib60","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S0140-6736(98)05012-0","article-title":"Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension","volume":"353","author":"Hansson","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.semnephrol.2005.02.004_bib61","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","article-title":"Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE)","volume":"359","author":"Dahlof","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.semnephrol.2005.02.004_bib62","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","article-title":"Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic","volume":"288","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.semnephrol.2005.02.004_bib63","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1016\/S0140-6736(04)16451-9","article-title":"Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine","volume":"363","author":"Julius","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.semnephrol.2005.02.004_bib64","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2005.02.004_bib65","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"issue":"suppl 3","key":"10.1016\/j.semnephrol.2005.02.004_bib66","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.1002\/dmrr.285","article-title":"Reduction of cardiovascular events and microvascular complications in diabetes with ACE inhibitor treatment","volume":"18","author":"Gerstein","year":"2002","journal-title":"Diabetes Metab Rev"},{"key":"10.1016\/j.semnephrol.2005.02.004_bib67","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/00004872-200103000-00020","article-title":"Follow-up of renal function in treated and untreated older patients with isolated systolic hypertension","volume":"19","author":"Voyaki","year":"2001","journal-title":"J Hypertens"},{"key":"10.1016\/j.semnephrol.2005.02.004_bib68","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1023\/A:1007882624572","article-title":"Therapeutic approaches to achieve desired blood pressure goals","volume":"14","author":"Koshy","year":"2000","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.semnephrol.2005.02.004_bib69","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1111\/j.1523-1755.2004.00620.x","article-title":"Differential effects of calcium antagonist subclasses on markers of nephropathy progression","volume":"65","author":"Bakris","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2005.02.004_bib70","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1161\/01.HYP.0000143851.23721.26","article-title":"Clinical Outcomes in the Diabetes Cohort of the International Verapamil SR-Trandolapril Study","volume":"44","author":"Bakris","year":"2004","journal-title":"Hypertension"},{"key":"10.1016\/j.semnephrol.2005.02.004_bib71","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1001\/jama.275.20.1557","article-title":"The progression from hypertension to congestive heart failure","volume":"275","author":"Levy","year":"1996","journal-title":"JAMA"},{"key":"10.1016\/j.semnephrol.2005.02.004_bib72","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1001\/jama.288.17.2144","article-title":"Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failure","volume":"288","author":"Kitzman","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.semnephrol.2005.02.004_bib73","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(03)14282-1","article-title":"Effects of candesartan on mortality and morbidity in patients with chronic heart failure","volume":"362","author":"Pfeffer","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.semnephrol.2005.02.004_bib74","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1001\/jama.277.9.739","article-title":"Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis","volume":"277","author":"Psaty","year":"1997","journal-title":"JAMA"},{"key":"10.1016\/j.semnephrol.2005.02.004_bib75","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2005.02.004_bib76","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1023\/A:1011119003788","article-title":"The EPHESUS trial: Eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study","volume":"15","author":"Pitt","year":"2001","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.semnephrol.2005.02.004_bib77","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","article-title":"Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both","volume":"349","author":"Pfeffer","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2005.02.004_bib78","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMoa010713","article-title":"A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure","volume":"345","author":"Cohn","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2005.02.004_bib79","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1056\/NEJM200001133420207","article-title":"Unstable angina pectoris","volume":"342","author":"Yeghiazarians","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2005.02.004_bib80","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1001\/jama.281.20.1927","article-title":"Meta-analysis of trials comparing beta-blockers, calcium antagonists, and nitrates for stable angina","volume":"281","author":"Heidenreich","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.semnephrol.2005.02.004_bib81","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S0140-6736(03)14286-9","article-title":"Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease","volume":"362","author":"Fox","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.semnephrol.2005.02.004_bib82","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1001\/jama.290.21.2805","article-title":"A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial","volume":"290","author":"Pepine","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.semnephrol.2005.02.004_bib83","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1046\/j.1523-1755.2003.00838.x","article-title":"Level of kidney function as a risk factor for cardiovascular outcomes in the elderly","volume":"63","author":"Manjunath","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2005.02.004_bib84","doi-asserted-by":"crossref","first-page":"563","DOI":"10.7326\/0003-4819-137-7-200210010-00007","article-title":"Acute myocardial infarction and renal dysfunction","volume":"137","author":"Wright","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semnephrol.2005.02.004_bib85","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1046\/j.1523-1755.2002.00638.x","article-title":"Incident acute coronary syndromes in chronic dialysis patients in the United States","volume":"62","author":"Trespalacios","year":"2002","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2005.02.004_bib86","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1016\/S0149-2918(01)80152-1","article-title":"Four-Year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other artihypertensive drug classes","volume":"23","author":"Conlin","year":"2001","journal-title":"Clin Ther"}],"container-title":["Seminars in Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S027092950500029X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S027092950500029X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,14]],"date-time":"2019-05-14T00:06:29Z","timestamp":1557792389000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S027092950500029X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,7]]},"references-count":86,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2005,7]]}},"alternative-id":["S027092950500029X"],"URL":"https:\/\/doi.org\/10.1016\/j.semnephrol.2005.02.004","relation":{},"ISSN":["0270-9295"],"issn-type":[{"value":"0270-9295","type":"print"}],"subject":[],"published":{"date-parts":[[2005,7]]}}}